by John Conrad | Aug 13, 2024 | NewsBrief
In a significant move that reshapes the landscape of the medical technology industry, Baxter International Inc. has announced a definitive agreement to sell its Kidney Care segment, soon to be renamed Vantive, to global investment firm Carlyle for $3.8 billion. This...
by John Conrad | Aug 9, 2024 | NewsBrief
In a recent emotional interview, acclaimed actor Colin Farrell opened up about his son James’s diagnosis of Angelman syndrome, a rare neurological condition that causes severe physical and learning disabilities. Farrell’s experience highlights the crucial...
by John Conrad | Aug 8, 2024 | NewsBrief
In a groundbreaking move set to transform diabetes management, Abbott and Medtronic have announced a global partnership aimed at integrating Abbott’s world-leading FreeStyle Libre continuous glucose monitoring (CGM) technology with Medtronic’s insulin...
by John Conrad | Aug 5, 2024 | NewsBrief
COUR Pharmaceutical has been recognized as one of Fierce Biotech’s “Fierce 15” companies for 2024, joining an elite group of innovators shaping the future of the biotech industry. This annual list, curated by Fierce Biotech, highlights 15 companies...
by John Conrad | Aug 5, 2024 | NewsBrief
COUR Pharmaceuticals, a clinical-stage biotech company focused on developing treatments for autoimmune and inflammatory diseases, has announced a significant leadership transition. Founder John J. Puisis will step down as President and Chief Executive Officer, handing...
by John Conrad | Aug 2, 2024 | NewsBrief
On August 1, 2024, AbbVie completed its acquisition of Cerevel Therapeutics, marking a significant milestone in the quest to improve treatments for millions of people living with neurological and psychiatric conditions. This union brings together two companies...
